Revive Therapeutics announces publication on potential of psilocybin

Revive Therapeutics (RVVTF) announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. Michael Frank, CEO of Revive, commented: “We have a diverse psilocybin-based pharmaceutical program that has been quietly moving forward with the aim of treating neurological, mental health and substance abuse disorders. The publication of the research study demonstrating psilocybin’s therapeutic potential in the treatment of stroke, which is often associated with subsequent depression, validates our strategic initiative to focus on evaluating psilocybin in clinical studies and novel delivery methods, such as our in-development psilocybin oral thin-film and microneedle patch.”